Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1972 8
1973 4
1974 3
1975 2
1976 2
1977 1
1978 1
1979 1
1980 3
1981 2
1982 2
1983 2
1984 3
1985 2
1986 7
1987 4
1988 9
1989 7
1990 7
1991 13
1992 17
1993 15
1994 14
1995 20
1996 20
1997 10
1998 10
1999 9
2000 11
2001 10
2002 9
2003 5
2004 7
2005 3
2006 5
2007 9
2008 10
2009 7
2010 4
2011 6
2012 7
2013 5
2014 4
2015 7
2016 3
2017 5
2018 4
2019 3
2020 3
2021 5
2022 5
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

322 results

Results by year

Filters applied: . Clear all
Page 1
Alpha emitter radium-223 and survival in metastatic prostate cancer.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators. Parker C, et al. Among authors: franzen l. N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755. N Engl J Med. 2013. PMID: 23863050 Free article. Clinical Trial.
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Björnlinger K, Seke M, Agrup M, Fransson P, Tavelin B, Norman D, Zackrisson B, Anderson H, Kjellén E, Franzén L, Nilsson P. Widmark A, et al. Among authors: franzen l. Lancet. 2019 Aug 3;394(10196):385-395. doi: 10.1016/S0140-6736(19)31131-6. Epub 2019 Jun 18. Lancet. 2019. PMID: 31227373 Clinical Trial.
Sucralfate: prophylaxis of mucosal damage during cancer therapy.
Henriksson R, Franzén L, Edbom C, Littbrand B. Henriksson R, et al. Among authors: franzen l. Scand J Gastroenterol Suppl. 1995;210:45-7. doi: 10.3109/00365529509090270. Scand J Gastroenterol Suppl. 1995. PMID: 8578206 Review.
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P, Nilsson P, Gunnlaugsson A, Beckman L, Tavelin B, Norman D, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Björnlinger K, Seke M, Agrup M, Zackrisson B, Kjellén E, Franzén L, Widmark A. Fransson P, et al. Among authors: franzen l. Lancet Oncol. 2021 Feb;22(2):235-245. doi: 10.1016/S1470-2045(20)30581-7. Epub 2021 Jan 11. Lancet Oncol. 2021. PMID: 33444529 Clinical Trial.
322 results